1
|
Jang HY, Kim YS, Oh JM. Clinical Effectiveness of Renal Transplant Outpatient Pharmaceutical Care Services in Korea. Healthcare (Basel) 2023; 11:2597. [PMID: 37761794 PMCID: PMC10531252 DOI: 10.3390/healthcare11182597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2023] [Revised: 09/18/2023] [Accepted: 09/20/2023] [Indexed: 09/29/2023] Open
Abstract
BACKGROUND The necessity and importance of pharmaceutical care services (PCS) are well recognized, yet the concept and scope of PCS have not yet been clearly defined in Korea, particularly in kidney transplantation outpatient clinics. AIM The main purpose of this study is to evaluate whether PCS is effective in the outpatient setting for kidney transplant patients. METHODS For three years, a clinical pharmacist provided PCS to kidney transplant patients in an outpatient setting to evaluate the clinical effectiveness of PCS. RESULTS A total of 302 patients were matched in a 1:1 ratio, with 151 in the PCS group and 151 in the control group. These patients were followed, and a total of 476 interventions were provided to them, including medication reconciliation (n = 113, 23.7%), medication evaluation and management (n = 186, 39.1%), and pharmaceutical care transition (n = 177, 37.2%) services. The estimated glomerular filtration rate (eGFR) exhibited a notable difference between the control and PCS groups when comparing the pre- and post-study periods measurements. In the control group, there was a decline of 7.0 mL/min/1.73 m2 in eGFR. In contrast, the PCS group showed a smaller decline of 2.5 mL/min/1.73 m2 (p = 0.03). The adjusted odds ratio for end stage renal disease development in the PCS group was 0.51 (95% confidence interval: 0.26-0.96), indicating a significantly lower risk compared to the control group. CONCLUSION Our study highlights the promising potential of PCS implementation in kidney transplantation outpatient clinics. Further research is needed to validate and expand upon these findings, especially in diverse clinical settings.
Collapse
Affiliation(s)
- Ha Young Jang
- College of Pharmacy, Gachon University, Incheon 21936, Republic of Korea;
- College of Pharmacy, Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea
| | - Yon Su Kim
- Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Republic of Korea;
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
| | - Jung Mi Oh
- College of Pharmacy, Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea
| |
Collapse
|
2
|
Liu J, Shi Y, Diao Y, Zeng X, Fu P. Strategies to Improve Long-Term Outcomes for Patients with Chronic Kidney Disease in China. KIDNEY DISEASES (BASEL, SWITZERLAND) 2023; 9:265-276. [PMID: 37899997 PMCID: PMC10601912 DOI: 10.1159/000530022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/18/2022] [Accepted: 02/17/2023] [Indexed: 10/31/2023]
Abstract
Background Chronic kidney disease (CKD) is an incurable disease requiring lifelong management. China has a high prevalence of CKD, which disproportionately affects older adults and those with chronic risk factors for CKD development. The rising prevalence of CKD in China places a substantial burden on the general population and the healthcare system. Summary In China, there are currently many unmet needs for patients with CKD and high-risk individuals, resulting from a lack of education and support to reduce risk factors, delayed diagnoses, limited knowledge of CKD among primary-care physicians, and poor access to treatments among some patient populations. An integrated, nationwide approach is required to improve the current situation of CKD management in China. There are currently several national healthcare frameworks in place that focus on new major health policies to prevent disease and encourage people to adopt healthier lifestyles, and while they do not directly target CKD, they may have a positive indirect impact. We explore the unmet needs for patients with CKD in China and discuss the potential strategies that may be required to overcome them. Such strategies include improving physician and patient education, establishing a targeted screening programme, supporting patients to improve self-management behaviours, accelerating the creation of medical consortia and medical satellite centres, and migrating from hospital- to community-based management. In addition to policy-driven strategies, development of novel therapies will be key to providing new solutions for the long-term management of CKD. Key Messages An integrated, nationwide approach is required, incorporating policy-driven changes to the clinical management of CKD, as well as the development of novel CKD treatments.
Collapse
Affiliation(s)
- Jing Liu
- Renal Division, West China Hospital of Sichuan University, Chengdu, China
- Kidney Research Institute, West China Hospital of Sichuan University, Chengdu, China
| | - Yunying Shi
- Renal Division, West China Hospital of Sichuan University, Chengdu, China
| | - Yongshu Diao
- Renal Division, West China Hospital of Sichuan University, Chengdu, China
| | - Xiaoxi Zeng
- Renal Division, West China Hospital of Sichuan University, Chengdu, China
- West China Biomedical Big Data Centre, West China Hospital, Sichuan University, Chengdu, China
| | - Ping Fu
- Renal Division, West China Hospital of Sichuan University, Chengdu, China
- Kidney Research Institute, West China Hospital of Sichuan University, Chengdu, China
| |
Collapse
|
3
|
Sánchez-García AM, Martínez-López P, Gómez-González AM, Rodriguez-Capitán J, Pavón-Morón FJ, Jiménez-López RJ, García-Almeida JM, Avanesi-Molina E, Zamboschi N, Rueda-Molina C, Doncel-Abad V, Molina-Ramos AI, Cabrera-César E, Ben-Abdellatif I, Gordillo-Resina M, Pérez-Mesa E, Nieto-González M, Nuevo-Ortega P, Reina-Artacho C, Sánchez-Fernández PL, Jiménez-Navarro MF, Estecha-Foncea MA. Post-Intensive Care Unit Multidisciplinary Approach in Patients with Severe Bilateral SARS-CoV-2 Pneumonia. Int J Med Sci 2023; 20:1-10. [PMID: 36619225 PMCID: PMC9812800 DOI: 10.7150/ijms.77792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Accepted: 11/06/2022] [Indexed: 12/23/2022] Open
Abstract
Background: Short and long-term sequelae after admission to the intensive care unit (ICU) for coronavirus disease 2019 (COVID-19) are to be expected, which makes multidisciplinary care key in the support of physical and cognitive recovery. Objective: To describe, from a multidisciplinary perspective, the sequelae one month after hospital discharge among patients who required ICU admission for severe COVID-19 pneumonia. Design: Prospective cohort study. Environment: Multidisciplinary outpatient clinic. Population: Patients with severe COVID-19 pneumonia, post- ICU admission. Methods: A total of 104 patients completed the study in the multidisciplinary outpatient clinic. The tests performed included spirometry, measurement of respiratory muscle pressure, loss of body cell mass (BCM) and BCM index (BCMI), general joint and muscular mobility, the short physical performance battery (SPPB or Guralnik test), grip strength with hand dynamometer, the six-minute walk test (6-MWT), the functional assessment of chronic illness therapy-fatigue scale (FACIT-F), the European quality of life-5 dimensions (EQ-5D), the Barthel index and the Montreal cognitive assessment test (MoCA). While rehabilitation was not necessary for 23 patients, 38 patients attended group rehabilitation sessions and other 43 patients received home rehabilitation. Endpoints: The main sequelae detected in patients were fatigue (75.96%), dyspnoea (64.42%) and oxygen therapy on discharge (37.5%). The MoCA showed a mean score compatible with mild cognitive decline. The main impairment of joint mobility was limited shoulder (11.54%) and shoulder girdle (2.88%) mobility; whereas for muscle mobility, lower limb limitations (16.35%) were the main dysfunction. Distal neuropathy was present in 23.08% of patients, most frequently located in lower limbs (15.38%). Finally, 50% of patients reported moderate limitation in the EQ-5D, with a mean score of 60.62 points (SD 20.15) in perceived quality of life. Conclusions: Our findings support the need for a multidisciplinary and comprehensive evaluation of patients after ICU admission for COVID-19 because of the wide range of sequelae, which also mean that these patients need a long-term follow-up. Impact on clinical rehabilitation: This study provides data supporting the key role of rehabilitation during the follow-up of severe patients, thus facilitating their reintegration in society and a suitable adaptation to daily living.
Collapse
Affiliation(s)
- Ana María Sánchez-García
- Instituto de Investigación Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Malaga, Spain
- Intensive Medicine Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain
| | - Pilar Martínez-López
- Instituto de Investigación Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Malaga, Spain
- Intensive Medicine Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain
| | - Adela María Gómez-González
- Instituto de Investigación Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Malaga, Spain
- Physical Medicine and Rehabilitation Service, Hospital Clínico Universitario Virgen de la Victoria, Malaga, Spain
| | - Jorge Rodriguez-Capitán
- Instituto de Investigación Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Malaga, Spain
- Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain
- Cardiology and Cardiac Surgery Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain
| | - Francisco-Javier Pavón-Morón
- Instituto de Investigación Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Malaga, Spain
- Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain
- Cardiology and Cardiac Surgery Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain
| | - Rafael José Jiménez-López
- Instituto de Investigación Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Malaga, Spain
- Family and Community Medicine Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain
| | - José Manuel García-Almeida
- Instituto de Investigación Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Malaga, Spain
- Cardiology and Cardiac Surgery Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain
| | - Elma Avanesi-Molina
- Instituto de Investigación Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Malaga, Spain
- Mental Health Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain
| | - Nicolás Zamboschi
- Instituto de Investigación Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Malaga, Spain
- Intensive Medicine Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain
| | - Carolina Rueda-Molina
- Instituto de Investigación Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Malaga, Spain
- Intensive Medicine Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain
| | - Victoria Doncel-Abad
- Instituto de Investigación Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Malaga, Spain
- Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain
- Cardiology and Cardiac Surgery Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain
| | - Ana Isabel Molina-Ramos
- Instituto de Investigación Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Malaga, Spain
- Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain
- Cardiology and Cardiac Surgery Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain
| | - Eva Cabrera-César
- Instituto de Investigación Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Malaga, Spain
- Pneumology Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain
| | - Imad Ben-Abdellatif
- Instituto de Investigación Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Malaga, Spain
- Intensive Medicine Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain
| | - Marina Gordillo-Resina
- Instituto de Investigación Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Malaga, Spain
- Intensive Medicine Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain
| | - Esteban Pérez-Mesa
- Instituto de Investigación Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Malaga, Spain
- Intensive Medicine Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain
| | - María Nieto-González
- Instituto de Investigación Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Malaga, Spain
- Intensive Medicine Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain
| | - Pilar Nuevo-Ortega
- Instituto de Investigación Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Malaga, Spain
- Intensive Medicine Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain
| | - Carmen Reina-Artacho
- Instituto de Investigación Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Malaga, Spain
- Intensive Medicine Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain
| | - Pedro Luis Sánchez-Fernández
- Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain
- Servicio de Cardiología, Hospital Universitario de Salamanca, Universidad de Salamanca, IBSAL, Salamanca, Spain
| | - Manuel Francisco Jiménez-Navarro
- Instituto de Investigación Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Malaga, Spain
- Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain
- Cardiology and Cardiac Surgery Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain
| | - María Antonia Estecha-Foncea
- Instituto de Investigación Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Malaga, Spain
- Intensive Medicine Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain
| |
Collapse
|
4
|
Jasińska-Stroschein M. The Effectiveness of Pharmacist Interventions in the Management of Patient with Renal Failure: A Systematic Review and Meta-Analysis. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2022; 19:11170. [PMID: 36141441 PMCID: PMC9517595 DOI: 10.3390/ijerph191811170] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 07/28/2022] [Revised: 08/30/2022] [Accepted: 09/02/2022] [Indexed: 06/16/2023]
Abstract
The existing trials have focused on a variety of interventions to improve outcomes in renal failure; however, quantitative evidence comparing the effect of performing multidimensional interventions is scarce. The present paper reviews data from previous randomized controlled trials (RCTs), examining interventions performed for patients with chronic kidney disease (CKD) and transplants by multidisciplinary teams, including pharmacists. Methods: A systematic search with quality assessment was performed using the revised Cochrane Collaboration's 'Risk of Bias' tool. Results and Conclusion: Thirty-three RCTs were included in the review, and the data from nineteen protocols were included in further quantitative analyses. A wide range of outcomes was considered, including those associated with progression of CKD, cardiovascular risk factors, patient adherence, quality of life, prescription of relevant medications, drug-related problems (DRPs), rate of hospitalizations, and death. The heterogeneity between studies was high. Despite low-to-moderate quality of evidence and relatively short follow-up, the findings suggest that multidimensional interventions, taken by pharmacists within multidisciplinary teams, are important for improving some clinical outcomes, such as blood pressure, risk of cardiovascular diseases and renal progression, and they improve non-adherence to medication among individuals with renal failure.
Collapse
|